REGISTERED
on 26 Nov 2024
Last Applicant/ Owned by
4 Kingdom Street, Paddington Central
London
GB
W26BD
Serial Number
97855624 filed on 24th Mar 2023
Registration Number
7575494 registered on 26th Nov 2024
Correspondent Address
Anna King
Filing Basis
1. intent to use
Disclaimer
NO DATA
GALOMIC
Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting gene Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; scientific and technical data analysis in relation to pharmaceuticals and medicines; scientific and technical data analysis in relation to RNAi-based medicines; scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for use in the field of pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations all for use in the fields of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation, all for use in the fields of pharmaceuticals, medicines, and drug discovery; design and development of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software for facilitating the targeted delivery of pharmaceutical and medical preparations, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software for facilitating the targeted delivery of pharmaceutical and medical preparations for silencing or inhibiting gene expression, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software for facilitating the targeted delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer for machine learning for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software using artificial intelligence for machine learning for facilitating the delivery of pharmaceutical and medical preparations, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software using artificial intelligence for machine learning for facilitating the delivery of pharmaceutical and medical preparations targeting genes and silencing or inhibiting gene expression, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software using artificial intelligence for machine learning for facilitating the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software using artificial intelligence for machine learning for facilitating the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression, all for use in the field of pharmaceuticals, medicines and drug delivery; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations databases all in the field of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation, all for use in the fields of pharmaceuticals, medicines and drug discovery; provision of information, advice and consultancy services relating to all of the aforesaid
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [009]
Computer & Software Products & Electrical & Scientific Products
Downloadable and recorded computer software for use in the field of pharmaceuticals, medicines and drug delivery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software for facilitating the targeted delivery of pharmaceutical and medical preparations; downloadable and recorded computer software for facilitating the targeted delivery of pharmaceutical and medical preparations for silencing or inhibiting gene expression; downloadable and recorded computer software for facilitating the targeted delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); downloadable and recorded computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug delivery; downloadable and recorded software using artificial intelligence for machine learning for facilitating the delivery of pharmaceutical and medical preparations; downloadable and recorded software using artificial intelligence for machine learning for facilitating the delivery of pharmaceutical and medical preparations targeting genes and silencing or inhibiting gene expression; downloadable and recorded software using artificial intelligence for machine learning for facilitating the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); downloadable and recorded software using artificial intelligence for machine learning for facilitating the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression; electronic databases for use in the field of pharmaceuticals, medicines and drug delivery recorded on computer media; electronic databases for use in the field of gene therapy recorded on computer media; electronic databases for use in the field of gene therapy, namely, the delivery of pharmaceutical and medical preparations recorded on computer media; electronic databases for use in the field of gene therapy, namely, the delivery of pharmaceutical and medical preparations targeting and silencing or inhibiting of genes recorded on computer media; electronic databases for use in the field of gene therapy, namely, the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs) recorded on computer media; downloadable and recorded computer platform software for use in the field of pharmaceuticals, medicines and drug delivery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software platforms for use in the field of pharmaceuticals, medicines and drug delivery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software for enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [040]
Treatment & Processing of Materials Services
Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of pharmaceutical preparations targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA-based (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 97855624
Mark Type
No Service Mark
Attorney Docket Number
No 210309.00128
44D Filed
Yes
44D Current
No
44E filed
No
44E Current
Yes
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 26th Nov 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 26th Nov 2024 | REGISTERED-PRINCIPAL REGISTER |
| 05th Nov 2024 | 1(B) BASIS DELETED; PROCEED TO REGISTRATION |
| 04th Nov 2024 | TEAS DELETE 1(B) BASIS RECEIVED |
| 04th Nov 2024 | NOTICE OF ALLOWANCE CANCELLED |
| 30th Apr 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 29th Apr 2024 | SOU EXTENSION 1 GRANTED |
| 29th Apr 2024 | SOU EXTENSION 1 FILED |
| 29th Apr 2024 | SOU TEAS EXTENSION RECEIVED |
| 28th Nov 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |